Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Technology
ALLISON GATLIN

Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600

Protagonist Therapeutics is poised to join the S&P SmallCap 600 next Wednesday, replacing copper and aluminum wire manufacturer Encore Wire.

The news sent Protagonist stock flying 8.9% to 34.65.

Protagonist Therapeutics is a clinical-stage biotech company working on treatments for blood disorders and immunological diseases. It's partnered with Takeda Pharmaceutical and Johnson & Johnson's Janssen division on its two leading drugs.

Shares recently broke out of a cup-with-handle base, topping a buy point at 32.64, MarketSurge chart analysis shows. Protagonist Therapeutics stock later fell as much as 6% below that entry on June 26. But the news Friday sent shares surging above that buy point again.

Notably, Protagonist stock has a strong Relative Strength Rating of 93 out of a total 99. This means the biotech stock ranks in the leading 7% of all stocks when it comes to 12-month performance, according to IBD Digital.

Protagonist Therapeutics stock also lands on the Russell 2000.

Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.